Nymox Pharmaceutical Corp. Company Profile (NASDAQ:NYMX)

Analyst Ratings

Consensus Ratings for Nymox Pharmaceutical Corp. (NASDAQ:NYMX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/14/2014Q314($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2014Q114$0.07$0.18 million$0.08 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2014($0.06)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q3($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2013Q1 2013($0.05)($0.03)$0.78 million$0.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2012Q312($0.06)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/20/2016James George RobinsonDirectorBuy10,000$3.33$33,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2016James George RobinsonDirectorBuy20,000$3.28$65,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2016James George RobinsonDirectorBuy17,500$3.53$61,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2016James George RobinsonDirectorBuy22,500$2.97$66,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016James George RobinsonDirectorBuy28,010$2.31$64,703.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/3/2016James George RobinsonDirectorBuy6,990$2.36$16,496.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2016James George RobinsonDirectorBuy15,000$2.27$34,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016James George RobinsonDirectorBuy39,500$2.39$94,405.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016James George RobinsonDirectorBuy20,500$2.40$49,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2016James George RobinsonDirectorBuy40,000$2.29$91,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016James George RobinsonDirectorBuy20,000$2.44$48,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2016James George RobinsonDirectorBuy95,000$2.90$275,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2015James George RobinsonDirectorBuy5,000$3.38$16,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015James George RobinsonDirectorBuy14,000$3.55$49,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015James George RobinsonDirectorBuy6,000$3.79$22,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015James George RobinsonDirectorBuy29,854$3.54$105,683.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2015James George RobinsonDirectorBuy63,334$3.56$225,469.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015James George RobinsonDirectorBuy46,812$3.51$164,310.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2015James George RobinsonDirectorBuy110,000$3.44$378,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015James George RobinsonDirectorBuy100,000$2.25$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)
DateHeadline
07/23/16 09:30 AMDirector of Nymox Pharmaceutical Corporatio (NASDAQ:NYMX), Robinson James George, buys 5,000 shares worth $16,400
07/21/16 08:27 AMNymox Pharmaceutical Corporation (NASDAQ:NYMX)'s Company Shares Increased 41.00% After Low Volatility - Press Telegraph
07/20/16 08:31 AMDoes Nymox Pharmaceutical Corporation Have Any Gas After Today's Huge Increase? - Press Telegraph
07/13/16 08:31 AMTuesday 7/12 Insider Buying Report: NYMX, EIGI
07/08/16 08:31 AMDirector of Nymox Pharmaceutical Corporatio (NASDAQ:NYMX), Robinson James George, buys 5,000 shares worth $17,100
07/07/16 08:30 AMHC Stocks Vigilant: CVS Health Corp (NYSE:CVS), Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - share market updates (press release)
06/29/16 05:28 PMNymox Pharmaceutical Corporation (NASDAQ:NYMX) Is Up 36% After The Call In 15-Week - Market News Call
06/29/16 05:28 PMStock to keep an eye on: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - News Oracle
06/27/16 05:29 PMNymox Pharmaceutical Corporation (NASDAQ:NYMX) Is Up 36% After The Call In 15-Week
06/27/16 09:46 AMNymox Pharmaceutical Corp. (NYMX) Is Accelerating To The Upside
06/25/16 05:05 PMDirector of Nymox Pharmaceutical Corporatio (NASDAQ:NYMX), Robinson James George, buys 5,000 shares worth $14,675
06/23/16 06:05 PMNYSE, NASDAQ Falling Stocks – DMTX, USEG, KEQU, CLBH, CNXR, NYMX, CETX
06/23/16 06:05 PMWhy Nymox Pharmaceutical Took Off
06/23/16 08:17 AMGaps Up Stocks Update - PRTO, TANH, USEG, KEQU, NYMX, CLBH, ASPN - FxPips.com
06/23/16 08:17 AM4 Stocks To Watch: AOSL, EXAS, GIMO, RTRX - Investing.com
06/23/16 08:17 AMNYMX Grabs Headlines, MRNS Awaits Data In 2H, PSTI Takes Small Step In DMD Race - RTT News
06/23/16 08:17 AMHC Stocks Indications: CVS Health Corp (NYSE:CVS), Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - share market updates (press release)
06/23/16 07:51 AMNymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data -
06/22/16 05:30 PMHere's Why These Five Stocks Are on the Move Today - Insider Monkey (blog)
06/22/16 05:30 PMUnusual 11 Mid-Day Movers 6/22: (ASPN) (NYMX) (CETX) Higher; (EBS) (CVTI) (TSLA) Lower - StreetInsider.com
06/22/16 05:30 PMNymox Pharmaceutical Corp. (NYMX) Is Sharply Higher On Study Results - RTT News
06/22/16 10:18 AMStudy Shows Major Reduction to Cumulative Incidence of Prostate Cancer in Study to 1.3%
06/22/16 10:18 AMNymox Pharma (NYMX) Announces Statistically Significant Data from Long-Term Fexapotide Study in Prostate Cancer vs. Placebo
06/22/16 10:18 AMNymox Pharmaceutical Corp. (NYMX) Is Sharply Higher On Study Results
06/22/16 08:46 AMNymox stock halted ahead of release of positive prostate cancer-prevention results -
06/22/16 08:30 AMNymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer - [GlobeNewswire] - HASBROUCK HEIGHTS, N.J., June 22, 2016-- Nymox Pharmaceutical Corporation announced today results from the Company's 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. ...
06/18/16 04:52 PMGaps Up - BCOM, ULBI, NYMX, XBIT, AFMD, AXDX, SGY - FxPips.com
06/16/16 09:47 AMGaps Up – BCOM, ULBI, NYMX, XBIT, AFMD, AXDX, SGY
05/16/16 05:11 PMNymox reports 1Q loss -
04/18/16 12:39 PMNymox Pharmaceutical Corporation (NYMX) and 2 Banks Witness Notable Insider Buying -
04/12/16 08:50 AMNymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q4, 2015 By the Numbers -
02/11/16 12:56 PMIn Focus Stocks: Nymox Pharmaceutical Corporation (NASDAQ:NYMX), Elmira Savings Bank (NASDAQ:ESBK ... - Property Mentor - In Focus Stocks: Nymox Pharmaceutical Corporation (NASDAQ:NYMX), Elmira Savings Bank (NASDAQ:ESBK ...Property MentorNymox Pharmaceutical Corporation (NASDAQ:NYMX) ended the last trading day at $2.14. Company weekly volatility is calculated as 14.32% and price to cash ratio as 455.93. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) showed a weekly ...and more »
02/10/16 12:59 PMHealthcare Unpredictable Gainers in Focus: ZIOPHARM Oncology (NASDAQ:ZIOP), Nymox Pharmaceutical (NASDAQ ... - Seneca Globe - Healthcare Unpredictable Gainers in Focus: ZIOPHARM Oncology (NASDAQ:ZIOP), Nymox Pharmaceutical (NASDAQ ...Seneca GlobeNymox Pharmaceutical Corporation (NASDAQ:NYMX) gains street interest as it closed at $2.28 by an ascending 16.92% with session volume was recorded 1.55 Million. Nymox Pharmaceutical Corporation (NYMX) reported that results from the completion of ...and more »
02/10/16 12:59 PMHigh Velocity Stocks: Intercontinental Exchange (NYSE:ICE), Nymox Pharmaceutical Corporation (NASDAQ:NYMX ... - Property Mentor - High Velocity Stocks: Intercontinental Exchange (NYSE:ICE), Nymox Pharmaceutical Corporation (NASDAQ:NYMX ...Property MentorNymox Pharmaceutical Corporation (NASDAQ:NYMX) caters to the Healthcare space. Its weekly performance is 11.76%. On the last day of trading company shares ended up at $2.28. Nymox Pharmaceutical Corporation (NASDAQ:NYMX) distance from ...and more »
02/09/16 12:26 PMNymox Pharma's (NYMX) Phase 2 NX03-0040 Trial of Fexapotide Triflutate Meets Primary Endpoint - StreetInsider.com - Nymox Pharma's (NYMX) Phase 2 NX03-0040 Trial of Fexapotide Triflutate Meets Primary EndpointStreetInsider.comNymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207). The study ...Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint StudyEconoTimesall 5 news articles »
02/09/16 12:26 PMNymox Pharmaceutical Corporation Has Another Very Strong Trading Session - Sonoran Weekly Review - Nymox Pharmaceutical Corporation Has Another Very Strong Trading SessionSonoran Weekly ReviewThe stock of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is a huge mover today! The stock is up 20.51% or $0.4 after the news, hitting $2.35 per share. About 900,043 shares traded hands or 261.83% up from the average. Nymox Pharmaceutical ...
02/09/16 09:00 AMNymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study - [GlobeNewswire] - HASBROUCK HEIGHTS, N.J., Feb. 09, 2016-- Nymox Pharmaceutical Corporation today announced results from the completion of the Company's U.S. 40 month localized prostate cancer Phase 2 NX03-0040 clinical ...
02/06/16 01:03 PMForm 6-K NYMOX PHARMACEUTICAL For: Feb 04 - StreetInsider.com - Form 6-K NYMOX PHARMACEUTICAL For: Feb 04StreetInsider.comHASBROUCK HEIGHTS, NJ (February 4, 2016) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today private placement equity investment of US$2.1 Million. The investment was at $2.00 per share with no warrants. The investment was ...
02/04/16 11:55 AMNymox Pharma (NYMX) Announces $2.1M in Equity Financing - StreetInsider.com - Nymox Pharma (NYMX) Announces $2.1M in Equity FinancingStreetInsider.comNymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today private placement equity investment of US$2.1 Million. The investment was at $2.00 per share with no warrants. The investment was made by long-term Nymox shareholders.Nymox Announces Additional $2.1 Million Equity FinancingGlobeNewswire (press release)all 6 news articles »
02/04/16 10:17 AM11:17 am Nymox Pharm announces additional $2.1 mln equity financing thru private placement at $2/share with no warrants by long-term shareholders -
02/04/16 10:15 AMNymox Announces Additional $2.1 Million Equity Financing - [GlobeNewswire] - HASBROUCK HEIGHTS, N.J., Feb. 04, 2016-- Nymox Pharmaceutical Corporation announced today private placement equity investment of US $2.1 Million. The investment was at $2.00 per share with no warrants. ...
02/01/16 11:26 AMCompany Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Drops by -6.85% - Bull Report - Company Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Drops by -6.85%Bull ReportNymox Pharmaceutical Corporation (NASDAQ:NYMX) has lost 6.85% during the past week and dropped 29.57% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 8.46%. Nymox ...
01/28/16 11:25 AMNymox Pharmaceutical Corporation (NASDAQ:NYMX) Short Interest Update - The Daily Rover - Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Short Interest UpdateThe Daily RoverNymox Pharmaceutical Corporation (NASDAQ:NYMX) has witnessed a rise of 5.7% or 92,189 shares in its short figure. The short interest augmentation took it from 1,615,610 on December 31,2015 to 1,707,799 on January 15,2016. In terms of floated shares, ...
01/25/16 10:53 AMCompany Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Rally 12.73% - WallStreet Prudent - Company Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Rally 12.73%WallStreet PrudentShares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) appreciated by 12.73% during the past week but lost 31.49% on a 4-week basis. The shares have outperformed the S&P 500 by 11.16% in the past week but underperformed the index by ...and more »
11/23/15 07:40 AMAnalyst Insights behind Price Movement - Research on Vascular Biogenics, Hutchinson Technology, Tonix Pharmaceuticals and Nymox Pharmaceutical - [Accesswire] - NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vascular ...
08/05/15 11:34 AMNymox Announces Appointment of James G. Robinson to Board of Directors - [at noodls] - Microsoft Word - PR 07-30-2015.doc For Further Information Contact: Paul Averback Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com NEWS RELEASE For Immediate Release: Nymox Announces Appointment ...
07/28/15 11:44 AMNymox Pharmaceutical (NYMX) Stock Higher on Positive Test Results -
07/28/15 09:36 AMNymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File For Regulatory Approvals For Fexapotide Triflutate (NX-1207). - [at noodls] - Microsoft Word - PR 07-27-2015.doc Contact: Paul Averback Nymox Pharmaceutical Corporation 800-93NYMOX www.nymox.com NEWS RELEASE For Immediate Release: HASBROUCK HEIGHTS, NJ (July 27, 2015) Nymox Pharmaceutical ...
07/28/15 09:36 AMNymox Appoints Cutler & Co. as Auditor - [at noodls] - Microsoft Word - PR 07-16-2015.doc For Further Information Contact: Paul Averback Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com NEWS RELEASE For Immediate Release: HASBROUCK HEIGHTS, NJ ...
07/27/15 11:36 PMNymox Pharmaceutical Corporation (NYMX) Jumps On News Of Study Results -

Social

About Nymox Pharmaceutical Corp.

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NYMX
  • CUSIP:
Key Metrics:
  • Previous Close: $3.97
  • 50 Day Moving Average: $3.03
  • 200 Day Moving Average: $2.51
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $177.81M
  • Beta: 0.71
  • Current Year EPS Consensus Estimate: $-0.20 EPS
  • Next Year EPS Consensus Estimate: $-0.57 EPS
Additional Links:
Nymox Pharmaceutical Corp. (NASDAQ:NYMX) Chart for Tuesday, July, 26, 2016